Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 4, 2010, Pages 310-316

  Naito, Takafumi ^a   Tokashiki, Shunsuke ^a,b   Mino, Yasuaki ^a   Otsuka, Atsushi ^a   Ozono, Seiichiro ^a   Kagawa, Yoshiyuki ^b   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CONCENTRATIVE NUCLEOSIDE TRANSPORTER 1; CYCLOSPORIN A; MIZORIBINE; NUCLEOSIDE TRANSPORTER; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DNA POLYMORPHISM; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CLEARANCE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; PRIORITY JOURNAL; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; BIOLOGICAL AVAILABILITY; CREATININE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; POLYMORPHISM, GENETIC; RIBONUCLEOSIDES; YOUNG ADULT;

EID: 77949460637     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00489.x     Document Type: Article

References (30)

1. Tanabe K, Tokumoto T, Ishikawa N, Kanematsu A, Oshima T, Harano M et al. Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression. Transplant Proc 1999;31:2877-9.
2. Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol 2005;64:28-34.
3. Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H et al. A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol 2004;8:117-26.
4. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol 2006;33:2153-61.
5. Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 1996;36:1081-92.
6. Takei S. Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Pediatr Int 2002;44:205-9.
7. Podgorska M, Kocbuch K, Pawelczyk T. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 2005;52:749-58.
8. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004;447:728-34.
9. Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M et al. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol 2007;293:R1809-22.
10. Mangravite LM, Badagnani I, Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 2003;479:269-81.
11. Okada M, Suzuki K, Nakashima M, Nakanishi T, Fujioka N. The nucleotide derivatives inosine and inosinic acid inhibit intestinal absorption of mizoribine in rats. Eur J Pharmacol 2006;531:140-4.
12. Mori N, Yokooji T, Kamio Y, Murakami T. Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats. Eur J Pharmacol 2008;586:52-8.
13. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003;13:675-82.
14. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004;75:422-33.
15. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006;82:1074-84.
16. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004;65:512-9.
17. Owen RP, Gray JH, Taylor TR, Carlson EJ, Huang CC, Kawamoto M et al. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet Genomics 2005;15:83-90.
18. Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 2007;63:459-68.
19. Ihara H, Shinkuma D, Kubo M, Miyamoto I, Nojima M, Koike H et al. Influence of bioavailability on blood level of mizoribine in kidney transplant recipients. Transplant Proc 1996;28:1321-3.
20. Ihara H, Shinkuma D, Nojima M, Koike H, Yabumoto H, Yamanaka Y et al. Clinical significance of blood level monitoring of mizoribine in kidney transplantation. Transplant Proc 1994;26:2029-31.
21. Sugitani A, Kitada H, Ota M, Yoshida J, Doi A, Hirakata H et al. Revival of effective and safe high-dose mizoribine for the kidney transplantation. Clin Transplant 2006;20:590-5.
22. Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc 1996;28:3643-8.
23. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A 2003;100:5896-901.
24. Li L, Tan CM, Koo SH, Chong KT, Lee EJ. Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics 2007;17:783-6.
25. Ishida K, Takaai M, Yotsutani A, Taguchi M, Hashimoto Y. Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LS180 cells. Biol Pharm Bull 2009;32:741-5.
26. Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S et al. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Ther Drug Monit 2008;30:656-61.
27. Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S et al. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients. J Clin Pharmacol 2009;49:710-8.
28. Elwi AN, Damaraju VL, Baldwin SA, Young JD, Sawyer MB, Cass CE. Renal nucleoside transporters: physiological and clinical implications. Biochem Cell Biol 2006;84:844-58.
29. Pastor-Anglada M, Errasti-Murugarren E, Aymerich I, Casado FJ. Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J Physiol Biochem 2007;63:97-110.
30. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001;276:2914-27.